Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment

(2016) Scott A. Tomlins et al.   EUROPEAN UROLOGY

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker–Based Risk Score

(2016) Leander Van Neste et al.   EUROPEAN UROLOGY

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy

(2016) James McKiernan et al.   JAMA Oncology

In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance

(2015) Francesco Porpiglia et al.   BJU INTERNATIONAL

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer

(2015) G. H. J. M. Leyten et al.   CLINICAL CANCER RESEARCH

A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer

(2015) Dipen J. Parekh et al.   EUROPEAN UROLOGY

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer

(2015) Tobias Nordström et al.   EUROPEAN UROLOGY

Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study

(2015) Nicola Fossati et al.   EUROPEAN UROLOGY

The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

(2015) Amanda Nicholson et al.   HEALTH TECHNOLOGY ASSESSMENT

A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result

(2015) M J Donovan et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy

(2015) Francesco Cantiello et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance

(2015) Francesco Cantiello et al.   WORLD JOURNAL OF UROLOGY

Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies

(2014) Stefano De Luca et al.   BJU INTERNATIONAL

Novel Tools to Improve Patient Selection and Monitoring on Active Surveillance for Low-risk Prostate Cancer: A Systematic Review

(2014) Roderick C.N. van den Bergh et al.   EUROPEAN UROLOGY

Comparative Evaluation of Urinary PCA3 and TMPRSS2: ERG Scores and Serum PHI in Predicting Prostate Cancer Aggressiveness

(2014) Lucile Tallon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Roles of Multiparametric Magnetic Resonance Imaging, PCA3 and Prostate Health Index—Which is the Best Predictor of Prostate Cancer after a Negative Biopsy?

(2014) Francesco Porpiglia et al.   JOURNAL OF UROLOGY

Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy

(2014) Thomas Seisen et al.   PROSTATE

Urinary biomarkers for prostate cancer: a review

(2013) Daphne Hessels et al.   ASIAN JOURNAL OF ANDROLOGY

Head-to-Head Comparison of Prostate Health Index and Urinary PCA3 for Predicting Cancer at Initial or Repeat Biopsy

(2013) Vincenzo Scattoni et al.   JOURNAL OF UROLOGY

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml

(2013) Matteo Ferro et al.   PLoS One

Recurrent Gene Fusions in Prostate Cancer: Their Clinical Implications and Uses

(2013) Daphne Hessels et al.   Current Urology Reports

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

(2012) A. Pettersson et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers

(2012) Matteo Ferro et al.   CLINICA CHIMICA ACTA

Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum [-2]Proprostate-Specific Antigen-Based Prostate Health Index for Detection of Prostate Cancer

(2012) C. Stephan et al.   CLINICAL CHEMISTRY

Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study

(2012) Meelan Bul et al.   EUROPEAN UROLOGY

Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer

(2012) Gisele H.J.M. Leyten et al.   EUROPEAN UROLOGY

Molecular Diagnosis of Prostate Cancer: PCA3 and TMPRSS2:ERG Gene Fusion

(2012) Maciej Salagierski et al.   JOURNAL OF UROLOGY

Toward the Detection of Prostate Cancer in Urine: A Critical Analysis

(2012) Matthew Truong et al.   JOURNAL OF UROLOGY

Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer

(2012) Jean-Nicolas Cornu et al.   PROSTATE

Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

(2012) Sisto Perdonà et al.   PROSTATE

Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting

(2011) Giorgio Guazzoni et al.   EUROPEAN UROLOGY

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

(2011) William J. Catalona et al.   JOURNAL OF UROLOGY

Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer

(2011) Simpa S. Salami et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?

(2010) Guillaume Ploussard et al.   BJU INTERNATIONAL

A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness

(2010) L. J. Sokoll et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication

(2010) Andrew Vickers et al.   JOURNAL OF CLINICAL ONCOLOGY

False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up

(2009) Tineke Wolters et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

TMPRSS2:ERGfusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis

(2009) KARI ROSTAD et al.   APMIS

Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer

(2009) J Nilsson et al.   BRITISH JOURNAL OF CANCER

Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context

(2009) G. Draisma et al.   JNCI-Journal of the National Cancer Institute

Screening and Prostate-Cancer Mortality in a Randomized European Study

(2009) Fritz H. Schröder et al.   NEW ENGLAND JOURNAL OF MEDICINE

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

(2008) Andrew J Vickers et al.   BMC Medicine